Name: Eprenetapopt (APR-246)
Brand: Selleck Chemicals
SKU: S7724
Availability: InStock
Rating: 5 (20 reviews)

Jump to

Quality Control

Batch: Purity: 99.69%

99.69

Related Targets	Bcl-2 Caspase PD-1/PD-L1 Ferroptosis Apoptosis related Synthetic Lethality STAT TNF-alpha Ras KRas
Other p53 Inhibitors	CBL0137 Hydrochloride Pifithrin-α (PFTα) Hhydrobromide Pifithrin-μ Serdemetan (JNJ-26854165) RITA PRIMA-1 NSC348884 NSC 319726 (ZMC1) Tenovin-6 Tenovin-1

Cell Culture, Treatment & Working Concentration

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
NALM-6	Cell viability assay			high sensitivity and cell death induction in all TP53mut leukemias, but low APR-246 sensitivity in TP53wt ALL	31073076
UoCB-6	Cell viability assay			high sensitivity and cell death induction in all TP53mut leukemias, but low APR-246 sensitivity in TP53wt ALL	31073076
EU-3	Cell viability assay			high sensitivity and cell death induction in all TP53mut leukemias, but low APR-246 sensitivity in TP53wt ALL	31073076
MUTZ-5	Cell viability assay			high sensitivity and cell death induction in all TP53mut leukemias, but low APR-246 sensitivity in TP53wt ALL	31073076
KOPN-8	Cell viability assay			high sensitivity and cell death induction in all TP53mut leukemias, but low APR-246 sensitivity in TP53wt ALL	31073076
RS4;11	Cell viability assay			high sensitivity and cell death induction in all TP53mut leukemias, but low APR-246 sensitivity in TP53wt ALL	31073076
SKBR3	Cell cycle assay	5 µM	2 weeks	lapatinib in combination with APR-246 caused a lower level of G1 arrest and an increase in the sub-G1 fraction	30743996
BT549	Cell viability assay			IC50=3.1 μM	30196236
MDA-MB-468	Cell viability assay			IC50=5 μM	30196236
MDA-MB-231	Cell viability assay			IC50=4.1 μM	30196236
HCC1143	Cell viability assay			IC50=6.8 μM	30196236
MDA-MB-453	Cell viability assay			IC50=0.9 μM	30196236
SKBR3	Cell viability assay			IC50=5.1 μM	30196236
UACC812	Cell viability assay			IC50=11.3 μM	30196236
MCF7	Cell viability assay			IC50=31.1 μM	30196236
MCF10A	Cell viability assay			IC50=5.2 μM	30196236
UMSCC10A	Cell viability assay	0-50 μM	72 h	suppressed cell survival and bore a modest effect on the killing of HNSCC cells	29348462
FaDu	Cell viability assay	0-50 μM	72 h	suppressed cell survival and bore a modest effect on the killing of HNSCC cells	29348462
TC32	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	29435139
DAOY	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	29435139
SJ-GBM2	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	29435139
A673	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	29435139
SK-N-MC	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	29435139
BT-37	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	29435139
NB-EBc1	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	29435139
Saos-2	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	29435139
SK-N-SH	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	29435139
NB1643	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	29435139
LAN-5	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	29435139
BT-12	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	29435139
OHS-50	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	29435139
MG 63 (6-TG R)	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	29435139
Rh41	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	29435139
Click to View More Cell Line Experimental Data

Solubility

In vitro
Batch:

DMSO : 40 mg/mL (200.75 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 40 mg/mL

Ethanol : 40 mg/mL

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	2.000mg/ml (10.04mM)
	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	2.000mg/ml (10.04mM)
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	199.25	Formula	C₁₀H₁₇NO₃	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	5291-32-7	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	PRIMA-1MET			Smiles	COCC1(C(=O)C2CCN1CC2)CO

Mechanism of Action

Targets/IC₅₀/Ki	Mutant p53
In vitro	Eprenetapopt (APR-246), also known as PRIMA-1MET, is the first clinical-stage compound that reactivates mutant p53 and induces apoptosis. It is a prodrug that is converted to the active compound methylene quinuclidinone (MQ), a Michael acceptor that binds to cysteine residues in mutant p53 and restores its wild-type conformation. This compound not only reactivates p53 but also decreases intracellular glutathione levels in a dose-dependent manner. It can trigger apoptosis in a p53-independent manner by inducing ROS and endoplasmic reticulum (ER) stress and by inhibiting thioredoxin reductase 1 (TrxR1). It was also reported that APR-246 induces cell death in myeloma cells independently of p53 status by impairing the GSH/ROS balance. PRIMA-1Met/APR-246 efficiently inhibited the growth of the SCLC cell lines expressing mutant p53 in vitro and induced apoptosis, associated with increased fraction of cells with fragmented DNA, caspase-3 activation, PARP cleavage, Bax and Noxa upregulation and Bcl-2 downregulation in the cells.
In vivo	In a Phase I/II clinical dose-finding study on hematological malignancies and prostate cancer, Eprenetapopt (APR-246) showed a good safety profile, and both clinical and p53-dependent biological responses were observed. It is well tolerated in animal studies, and single treatment with this compound inhibits tumor growth by 21% in mice bearing the aggressively growing A2780-CP20 tumor xenografts.
References	[1] https://pubmed.ncbi.nlm.nih.gov/26086967/ [2] https://pubmed.ncbi.nlm.nih.gov/21415220/

Applications

Methods	Biomarkers	Images	PMID
Western blot	FL-PARP / Cleaved PARP p-p53		26452133
Growth inhibition assay	Cell viability		26452133

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04383938	Completed	Bladder Cancer\|Gastric Cancer\|Non Small Cell Lung Cancer\|NSCLC\|Urothelial Carcinoma\|Advanced Solid Tumor	Aprea Therapeutics	June 25 2020	Phase 1\|Phase 2
NCT04214860	Completed	Myeloid Malignancy	Aprea Therapeutics	December 13 2019	Phase 1
NCT03391050	Terminated	Melanoma	Aprea Therapeutics\|Jules Bordet Institute	January 18 2018	Phase 1\|Phase 2
NCT02999893	Terminated	Oesophageal Carcinoma	Peter MacCallum Cancer Centre Australia	April 11 2017	Phase 1\|Phase 2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Eprenetapopt (APR-246) p53 activator

Chemical Structure

Molecular Weight: 199.25